[{"data":1,"prerenderedAt":211},["ShallowReactive",2],{"drug-alprazolam":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":58,"contraindications":106,"warnings":116,"renal":117,"monitoring":118,"interactions":119,"review":120,"examples":123,"atc":132,"iran":134,"links":154,"populations":171,"usApproval":206},"alprazolam",1,{"fa":7,"en":8},"آلپرازولام","Alprazolam","nervous-system",{"fa":11,"en":12},"بنزودیازپین","Benzodiazepine",[14],{"name":15,"market":16},"Xanax","US",[18,19,7],"xanax","زاناکس",[21,35,43,50],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-0-25","tablet","oral","0.25 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},0.25,"mg",true,[16],[32],{"source":33,"section":34},"fda-xanax","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-0-5","0.5 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},0.5,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":47,"refs":48},"tab-1","1 mg tablet",{"amount":5,"unit":28,"perUnit":23,"scored":29},[16],[49],{"source":33,"section":34},{"id":51,"form":23,"route":24,"label":52,"concentration":53,"markets":55,"refs":56},"tab-2","2 mg tablet",{"amount":54,"unit":28,"perUnit":23,"scored":29},2,[16],[57],{"source":33,"section":34},[59,87],{"id":60,"disease":60,"label":61,"population":64,"type":68,"unit":28,"dose":69,"refs":71,"limits":74,"notes":78},"gad",{"fa":62,"en":63},"اضطراب فراگیر — بزرگسال: ۰٫۲۵ تا ۰٫۵ mg سه بار در روز","GAD — adults: 0.25–0.5 mg three times daily",{"minAge":65},{"value":66,"unit":67},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":70},3,[72],{"source":33,"section":73},"2.1",{"maxPerDay":75,"refs":76},4,[77],{"source":33,"section":73},[79],{"text":80,"refs":83},{"fa":81,"en":82},"تنظیم هر ۳ تا ۴ روز؛ قطع تدریجی (حداکثر ۰٫۵ mg هر ۳ روز).","Adjust every 3–4 days; taper gradually (≤0.5 mg every 3 days).",[84,85],{"source":33,"section":73},{"source":33,"section":86},"2.3",{"id":88,"disease":89,"label":90,"population":93,"type":68,"unit":28,"dose":95,"refs":96,"notes":99},"panic","panic-disorder",{"fa":91,"en":92},"پانیک — بزرگسال: ۰٫۵ mg سه بار در روز","Panic disorder — adults: 0.5 mg three times daily",{"minAge":94},{"value":66,"unit":67},{"perDose":39,"dosesPerDay":70},[97],{"source":33,"section":98},"2.2",[100],{"text":101,"refs":104},{"fa":102,"en":103},"افزایش هر ۳ تا ۴ روز حداکثر ۱ mg\u002Fday؛ در مطالعات ۱ تا ۱۰ mg\u002Fday.","Increase every 3–4 days by ≤1 mg\u002Fday; studies used 1–10 mg\u002Fday.",[105],{"source":33,"section":98},[107],{"id":108,"severity":109,"text":110,"refs":113},"ci","block",{"fa":111,"en":112},"حساسیت به بنزودیازپین‌ها؛ مهارکننده‌های قوی CYP3A (کتوکونازول، ایتراکونازول).","Hypersensitivity to benzodiazepines; strong CYP3A inhibitors (ketoconazole, itraconazole).",[114],{"source":33,"section":115},"4",[],[],[],[],{"status":121,"reviewer":122,"date":122},"unverified",null,[124,129],{"regimen":60,"formulation":22,"input":125,"expect":128},{"ageYears":126,"weightKg":127},30,70,{"perDose":27,"upperPerDose":39},{"regimen":88,"formulation":36,"input":130,"expect":131},{"ageYears":126,"weightKg":127},{"perDose":39},[133],"N05BA12",{"status":135,"forms":136,"refs":149},"registered",[137,141,145],{"code":138,"en":139,"fa":140},"00040","ALPRAZOLAM 0.5MG TAB","قرص آلپرازولام ۰٫۵ میلی‌گرم",{"code":142,"en":143,"fa":144},"01382","ALPRAZOLAM 1MG TAB","قرص آلپرازولام ۱ میلی‌گرم",{"code":146,"en":147,"fa":148},"52892","ALPRAZOLAM 2MG TAB","قرص آلپرازول ۲ میلی‌گرم",[150],{"source":151,"section":152,"url":153},"darooyab-generic","G-1223\u002FAlprazolam","https:\u002F\u002Fwww.darooyab.ir\u002FG-1223\u002FAlprazolam",[155,159,163,166,169],{"kind":156,"url":157,"label":158},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=018276","NDA018276",{"kind":160,"url":161,"label":162},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=bb5cf72e-3a41-41a8-9a38-80f974eca33f","FDA Xanax",{"kind":164,"url":165,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa684001.html",{"kind":167,"url":168,"label":133},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N05BA12",{"kind":170,"url":153,"label":8},"darooyab",{"pregnancy":172,"lactation":181,"pediatric":190,"geriatric":198},{"level":173,"text":174,"quote":177,"refs":178},"caution",{"fa":175,"en":176},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and\u002For neonatal withdrawal [see Warnings and Precautions (5.8) and Clinical Considerations) ].",[179],{"source":33,"section":180},"8.1",{"level":182,"text":183,"quote":186,"refs":187},"avoid",{"fa":184,"en":185},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions, including sedation and withdrawal symptoms in breastfed infants, advise patients that breastfeeding is not recommended during treatment with XANAX.",[188],{"source":33,"section":189},"8.2",{"level":173,"text":191,"quote":194,"refs":195},{"fa":192,"en":193},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of XANAX have not been established in pediatric patients.",[196],{"source":33,"section":197},"8.4",{"level":173,"text":199,"quote":202,"refs":203},{"fa":200,"en":201},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","XANAX-treated geriatric patients had higher plasma concentrations of alprazolam (due to reduced clearance) compared to younger adult patients receiving the same doses.",[204],{"source":33,"section":205},"8.5",{"kind":207,"refs":208,"id":158},"NDA",[209],{"source":33,"section":210},"SPL approval \u002F marketing category",1792191877024]